The allegations centered around the rebates the EpiPen-maker offered the government. The makers of generic drugs pay rebates of 13 percent, but manufacturers of brand-name drugs must offer discounts of about 23 percent.

The New York Times:
Mylan To Settle EpiPen Overpricing Case For $465 Million
Mylan, the maker of the allergy treatment EpiPen, said Friday that it had reached a $465 million settlement with the Justice Department and other government agencies over questions on whether the company had overcharged Medicaid for the treatment by improperly classifying it as a generic drug. The federal government said this week that Mylan had been told multiple times that it was wrongly classifying the EpiPen, which led the Medicaid and Medicare programs to overpay for the product. (Thomas, 10/7)

Mylan To Pay $465 Million To Settle Claims Of Shortchanging Medicaid
Mylan reached a $465 million settlement on Friday with the US Department of Justice and other government agencies over …
Go to Source

Mylan To Pay $465M To Settle Allegations It Overcharged Medicaid